LB-201 (Centessa Pharmaceuticals)

N/A

Report date: 2026/03/19 17:16:41

Base Information

Drug NameLB-201 (Centessa Pharmaceuticals)
Drug Alias NameLB-201 (Centessa Pharmaceuticals)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Programmed death-ligand 1Anti-CD3
TargetsProgrammed death-ligand 1T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCentessa Pharmaceuticals Plc
China Registration ClassN/A

Develop Information

Active CompaniesCentessa Pharmaceuticals Plc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A